Evidence map›Paper›PMID 27294543›Full record

ArticleBiomaterials2016

Affinity-controlled protein encapsulation into sub-30 nm telodendrimer nanocarriers by multivalent and synergistic interactions.

Xu Wang, Changying Shi, Li Zhang, Alexa Bodman, Dandan Guo, Lili Wang, Walter A Hall, Stephan Wilkens, Juntao Luo

Abstract read
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xu WangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Changying ShiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Li ZhangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Department of Applied Chemistry, China Agricultural University, Beijing, 100193, PR China.
Alexa BodmanDepartment of Neurosurgery, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Dandan GuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Lili WangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Walter A HallDepartment of Neurosurgery, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Stephan WilkensDepartment of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Juntao LuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, NY 13210, United States. Electronic address: LuoJ@upstate.edu.
SUNY Upstate Medical University · USChina Agricultural University · CN

Funding

Size-tunable cancer nanotherapeuticsR01CA140449 · NCI · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2010 to 2014
$1.6M
An innovative hemoperfusion nanotrap for sepsis treatment.R01GM130941 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2018 to 2021
$1.5M
Rational Design and High throughput synthesis of nanocarriers for efficient drug deliveryR21EB019607 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2015 to 2016
$453k
NCI NIH HHS R01 CA140449NIBIB NIH HHS R21 EB019607
6 · The paper itself

Abstract

Novel nanocarriers are highly demanded for the delivery of heterogeneous protein therapeutics for disease treatments. Conventional nanoparticles for protein delivery are mostly based on the diffusion-limiting mechanisms, e.g., physical trapping and entanglement. We develop herein a novel linear-dendritic copolymer (named telodendrimer) nanocarrier for efficient protein delivery by affinitive coating. This affinity-controlled encapsulation strategy provides nanoformulations with a small particle size (<30 nm), superior loading capacity (>50% w/w) and maintained protein bioactivity. We integrate multivalent electrostatic and hydrophobic functionalities synergistically into the well-defined telodendrimer scaffold to fine-tune protein binding affinity and delivery properties. The ion strength and density of the charged groups as well as the structure of the hydrophobic segments are important and their combinations in telodendrimers are crucial for efficient protein encapsulation. We have conducted a series of studies to understand the mechanism and kinetic process of the protein loading and release, utilizing electrophoresis, isothermal titration calorimetry, Förster resonance energy transfer spectroscopy, bio-layer interferometry and computational methods. The optimized nanocarriers are able to deliver cell-impermeable therapeutic protein intracellularly to kill cancer cells efficiently. In vivo imaging studies revealed cargo proteins preferentially accumulate in subcutaneous tumors and retention of peptide therapeutics is improved in an orthotopic brain tumor, these properties are evidence of the improved pharmacokinetics and biodistributions of protein therapeutics delivered by telodendrimer nanoparticles. This study presents a bottom-up strategy to rationally design and fabricate versatile nanocarriers for encapsulation and delivery of proteins for numerous applications.

Indexed as

AnimalsCell Line, TumorDendrimersDrug Delivery SystemsFemaleHumansHydrophobic and Hydrophilic InteractionsMiceMice, NudeModels, MolecularNanocapsulesNeoplasmsProteinsStatic ElectricityDendrimersNanocapsulesProteinsAffinity-controlled encapsulationMultivalent interactionsNanoparticlesProtein deliverySynergistic effectsTelodendrimers

Identifiers

PMID27294543
PMCPMC4921341
OpenAlexW2409236694

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.